MRI-derived markers for predicting a decline in renal function in patients with autosomal dominant polycystic kidney disease

Ewa Banach-Ambroziak; Magdalena Jankowska; Małgorzata Grzywińska; Joanna Pieńkowska; Edyta Szurowska

doi:10.5114/pjr.2019.87763

MRI-derived markers for predicting a decline in renal function in patients with autosomal dominant polycystic kidney disease

Pol J Radiol. 2019 Aug 9:84:e289-e294. doi: 10.5114/pjr.2019.87763. eCollection 2019.

Authors

Ewa Banach-Ambroziak¹, Magdalena Jankowska², Małgorzata Grzywińska³, Joanna Pieńkowska⁴, Edyta Szurowska⁴

Affiliations

¹ University Medical Centre of Gdansk, Poland.
² Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Poland.
³ Department of Human Physiology, Medical University of Gdansk, Poland.
⁴ Second Department of Radiology, Medical University of Gdansk, Poland.

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) constitutes the fourth cause of end-stage renal disease in Europe. The course of the disease varies widely among patients with ADPKD. Due to the emergence of new possibilities of pharmacotherapy, it has become crucial to identify the group of patients with the fastest rate and risk of disease progression. This particular group of patients will benefit most from the therapy and they are the best candidates for clinical trials. At the early stages of ADPKD typical markers of severity and progression of the disease remain unchanged in contrast to the kidney volume, which increases continuously in an exponential way. Therefore, the use of height-adjusted total kidney volume as a biomarker should become a mandatory diagnostic option. Also, quantitative MRI techniques are promising biomarkers for the evaluation of disease severity and could provide additional insights into its course.

Keywords: MRI; autosomal dominant polycystic kidney disease; total kidney volume.

Publication types

Review